查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1464742

急性呼吸窘迫症候群市場：按類型、原因和最終用戶分類 - 全球預測 2024-2030

Acute Respiratory Distress Syndrome Market by Type (Diagnostics, Treatment), Cause (Direct Lung Injury, Indirect Lung Injury), End-user - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年急性呼吸窘迫症候群市場規模為25.6億美元，預計2024年將達27.2億美元，2030年將達38.9億美元，複合年成長率為6.13%。

急性呼吸窘迫症候群（ARDS）是一種嚴重的肺部疾病，其特徵是肺部快速發生廣泛的發炎。 ARDS 是一種呼吸衰竭，當液體在肺部的小彈性氣囊（肺泡）中積聚時就會發生。這種液體會阻止肺部充滿足夠的空氣，因此到達血液的氧氣就會減少。 ARDS 市場的產品和服務應用於重症加護環境，例如加護病房(ICU) 和醫院急診室，治療嚴重呼吸衰竭患者。有幾個因素正在影響 ARDS 市場的成長。 ARDS 盛行率的不斷增加，加上敗血症、創傷和感染疾病的增加，正在推動對有效治療方法的需求。機械通氣和支援護理方面的技術進步正在促進市場成長。此外，醫療保健專業人員對新藥研發的日益關注以及對 ARDS 的認知和理解不斷增強，也正在推動市場向前發展。儘管預計會成長，但 ARDS 市場面臨著治療成本高和低收入地區獲得先進醫療服務有限等挑戰，限制了市場擴張。此外，ARDS 的複雜性、患者對治療的不同反應以及對病理生理學的了解不足，使普遍有效的治療方法的開發變得複雜。另一方面，針對 ARDS 分子和免疫學基礎的個人化醫療方法的開發提供了巨大的商機。此外，隨著醫療基礎設施投資的增加，新興市場的擴張也提供了新的成長途徑。學術和研究機構與工業界在開發創新治療方法方面的合作也正在擴大潛力。

主要市場統計
基準年[2023] 25.6億美元
預測年份 [2024] 27.2億美元
預測年份 [2030] 38.9億美元
複合年成長率（%） 6.13%

類型：可望應用於精準醫療，診斷需求不斷增加

ARDS 的準確診斷對於及時開始治療至關重要。診斷領域主要分為診斷影像、血液檢測和分子診斷。診斷影像主要包括胸部 X 光檢查和電腦斷層掃描，以檢測肺泡內是否有液體。 電腦斷層掃描提供詳細的影像，有助於區分 ARDS 和其他疾病。血液檢查用於測量氧氣水平並識別潛在的感染疾病。血液檢查對於診斷 ARDS 至關重要，但僅靠血液檢查並不能確診病情。由於其早期檢測和嚴重性評估的潛力，該領域預計將會成長。 ARDS 的治療方法多種多樣，包括機械通氣、藥物治療和實驗治療。機械通氣是 ARDS 患者的重要介入措施，有助於維持氧合。飛利浦醫療保健和美Medtronic的高階人工呼吸器因其先進的功能而備受青睞，可最大限度地提高患者舒適度並改善治療結果。藥物包括皮質類固醇和抗生素，分別用於控制發炎和感染疾病。實驗性治療包括幹細胞療法和 ECMO（體外膜氧氣療法）。儘管仍在研究中，但這些治療方法顯示出改善 ARDS 預後的潛力。 ARDS 市場顯示出巨大的成長潛力，其進步主要體現在診斷領域，特別是分子診斷，因為其在精準醫療中的潛在應用。然而，與尖端診斷影像設備和先進治療設備相關的高成本可能會給某些市場帶來可近性挑戰。治療性介入，特別是機械通氣和實驗治療，正在經歷創新性的改進，以提高患者的生存率並最大限度地減少併發症。

最終用戶：擴大醫院對 ARDS 管理的偏好

醫院是治療 ARDS 的前線戰士，提供從機械通氣到體外膜氧合 (ECMO) 的全面護理。醫院基於需求的偏好主要圍繞在提供多學科護理和先進生命維持管理系統的能力。專注於肺部和呼吸護理的專科診所為 ARDS 管理提供專門服務，包括但不限於肺部復健和標靶治療。這些診所為需要長期急性後專門治療的 ARDS 患者以及輕度至中度 ARDS 患者提供服務。由於其規模和設施齊全，醫院通常設備齊全，可以處理需要多專科干預和高級支援護理的嚴重 ARDS 病例。醫院具有整合不同專業的優勢，確保對病人進行整體管理。

區域洞察

美洲，特別是美國和加拿大，對急性呼吸窘迫症候群(ARDS) 的先進治療有巨大需求。這些地區 ARDS 的高盛行率，加上強大的醫療基礎設施，正在推動市場的顯著成長。美洲客戶的購買行為傾向於創新和實證治療，反映出他們對先進醫療技術和藥物干預措施的信任。在南美洲，ARDS治療和診斷市場正在逐漸擴大，以巴西和阿根廷為首，這兩個國家正在投資醫療基礎設施和臨床研究。歐洲是 ARDS 的重要市場，西歐國家在研究、治療方法採用和市場收益方面處於領先地位。該地區受益於強大的醫療保健系統和先進治療方法的廣泛採用。此外，針對 ARDS 的眾多措施和合作研究工作正在進行中，這增加了有效管理策略的迫切性。同時，中東和非洲面臨獨特的挑戰，包括獲得醫療服務的機會有限以及某些地區缺乏專門的醫療設施。但由於認知的提高和醫療費用的增加，這些地區的ARDS治療情況正在逐漸改善。在醫療保健成本上升和人口成長的推動下，亞太地區 ARDS 治療和診斷市場正在快速成長。中國、日本和印度由於人口眾多且呼吸道疾病盛行率不斷上升，正在推動這項成長。該地區的研究舉措和最先進治療的採用也顯著增加。政府改善醫療保健系統的舉措進一步推動亞太市場向前發展。

FPNV定位矩陣

FPNV 定位矩陣對於評估急性呼吸窘迫症候群症候群市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對急性呼吸窘迫症候群症候群市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.急性呼吸窘迫症候群市場的市場規模與預測是多少？

2.在急性呼吸窘迫症候群市場預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.急性呼吸窘迫症候群市場的技術趨勢和法規結構是什麼？

4.急性呼吸窘迫症候群市場主要供應商的市場佔有率是多少？

5. 進入急性呼吸窘迫症候群症候群市場適合的型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 由於敗血症、創傷和感染疾病發生率增加，ARDS 盛行率增加
      • 人工呼吸器和支持治療的進展
      • 新藥研發日益受到重視
    • 抑制因素
      • 治療費用高昂，獲得先進醫療服務的機會有限
    • 機會
      • 個人化醫療方法的持續發展
      • 政府措施和增加醫療基礎設施投資
    • 任務
      • 核准新治療方法和設備的監管複雜性；
  • 市場區隔分析
    • 類型：由於精準醫學的潛在應用，診斷需求不斷增加
    • 最終用戶：擴大醫院在管理 ARDS 方面的優先級
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章急性呼吸窘迫症候群市場：依類型

  • 診斷
  • 過程

第7章急性呼吸窘迫症候群市場：依原因分類

  • 直接肺損傷
  • 間接肺損傷

第8章急性呼吸窘迫症候群市場：依最終用戶分類

  • 醫院
  • 專科診所

第9章美洲急性呼吸窘迫症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太地區急性呼吸窘迫症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲急性呼吸窘迫症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 市場佔有率分析（2023）
  • FPNV定位矩陣（2023）
  • 競爭場景分析
    • BioAegis 與 BARDA 簽訂 2000 萬美元契約，開發 ARDS 治療藥物
    • Veru Inc. 同意 FDA 對 Sabavibrin 進行新的 III 期臨床試驗，其適應症廣泛，適用於因所有類型的病毒性急性呼吸窘迫症候群(ARDS) 住院的成年患者
  • 戰略分析和建議

第13章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4E447E7FCAAC

[196 Pages Report] The Acute Respiratory Distress Syndrome Market size was estimated at USD 2.56 billion in 2023 and expected to reach USD 2.72 billion in 2024, at a CAGR 6.13% to reach USD 3.89 billion by 2030.

Acute respiratory distress syndrome (ARDS) is a severe lung condition characterized by rapid onset of widespread inflammation in the lungs. ARDS is a type of respiratory failure that occurs when fluid is produced in the tiny, elastic air sacs (alveoli) in the lungs. The fluid controls the lungs from filling with sufficient air, which means less oxygen reaches the bloodstream. Products and services in the ARDS market are applied in critical care settings, including intensive care units (ICUs) in hospitals and emergency departments, where patients with severe respiratory failure receive treatment. Several factors influence the growth of the ARDS market. The increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections, drives the demand for effective treatments. Technological advancements in mechanical ventilation and supportive therapies contribute to market growth. Additionally, the heightened focus on research and development of new pharmaceuticals and the expanding awareness and understanding of ARDS among healthcare providers propel the market forward. Despite growth prospects, the ARDS market faces challenges such as high treatment costs and limited accessibility to advanced care in low-income regions that restrict market expansion. Furthermore, the complexity of ARDS, variability in patient response to treatments, and a still-evolving understanding of its pathophysiology make developing universally effective treatments challenging. On the other hand, the development of personalized medicine approaches targeting the molecular and immunological underpinnings of ARDS presents a significant opportunity. Additionally, expanding markets in emerging economies, with increasing healthcare infrastructure investments, offer new avenues for growth. Collaboration between academic, research institutions, and industry in developing innovative therapies also opens up potential opportunities.

KEY MARKET STATISTICS
Base Year [2023] USD 2.56 billion
Estimated Year [2024] USD 2.72 billion
Forecast Year [2030] USD 3.89 billion
CAGR (%) 6.13%

Type: Increasing need for diagnostics due to its potential for precision medicine application

Accurate diagnosis of ARDS is pivotal for initiating timely treatment. The diagnostics segment is principally categorized into Imaging, Blood Tests, and Molecular diagnostics. Imaging primarily involves Chest X-rays and CT Scans to detect the presence of fluid in the alveoli. Need-based preference leans towards CT scans for their detailed imagery, aiding in the discernment of ARDS from other conditions. Blood tests are utilized for measuring oxygen levels and identifying potential infections. These are integral for ARDS diagnosis, though they cannot solely confirm the condition. Molecular diagnostics focusing on genetic markers and biomarkers associated with ARDS. This segment is expected to grow, given its potential for early detection and assessment of disease severity. Treatment modalities for ARDS are diverse, encompassing Mechanical Ventilation, Drug Therapy, and Experimental Therapies. Mechanical ventilation is a crucial intervention for ARDS patients, helping maintain oxygenation. High-end ventilators from Philips Healthcare and Medtronic are highly preferred for their advanced features, which maximize patient comfort and improve outcomes. Drug therapy includes corticosteroids and antibiotics, among other medications, to manage inflammation and infections, respectively. Experimental therapies include stem cell therapy and ECMO (Extracorporeal Membrane Oxygenation). While still under investigation, these treatments show promise for improving ARDS outcomes. The ARDS market exhibits significant growth potential, with advancements predominantly observed in the diagnostics segment, particularly in molecular diagnostics, due to its potential for precision medicine applications. However, the high costs associated with state-of-the-art imaging equipment and advanced therapeutic devices could pose accessibility challenges in certain markets. Treatment interventions, specifically mechanical ventilation and experimental therapies, are witnessing innovative enhancements to improve patient survival rates and minimize complications.

End-user: Expanding preference for hospitals for management of ARDS

Hospitals are the frontline warriors in the management of ARDS, providing comprehensive care ranging from mechanical ventilation to extracorporeal membrane oxygenation (ECMO). The need-based preference in hospitals primarily revolves around the capability to offer multi-disciplinary care and advanced life support systems. Specialty Clinics focusing on pulmonary and respiratory care offer specialized services for ARDS management, including but not limited to pulmonary rehabilitation and targeted medical therapies. These clinics cater to ARDS patients with a need for prolonged, specialized care post-acute phase or those with mild to moderate ARDS. Hospitals, given their scale and comprehensive facilities, are often better equipped to manage severe cases of ARDS that require multi-specialty intervention and advanced supportive care. They benefit from the integration of various specialties, ensuring a holistic approach to patient management.

Regional Insights

The Americas, particularly the United States and Canada, have shown a significant need for advanced treatments for acute respiratory distress syndrome (ARDS). The high prevalence of ARDS in these regions, compounded by robust healthcare infrastructure, has facilitated substantial market growth. Customer purchasing behavior in the Americas tends to lean towards innovative, evidence-based treatments, reflecting a trust in advanced medical technology and pharmaceutical interventions. In South America, the market for ARDS treatments and diagnostics is gradually expanding, with Brazil and Argentina at the forefront, investing in healthcare infrastructure and clinical research. Europe represents a significant market for ARDS, with Western European countries are at forefront in terms of research, treatment adoption, and market revenues. The region benefits from strong healthcare systems and widespread adoption of advanced therapeutics. Moreover, numerous initiatives and collaborations aim to address ARDS, elevating the urgency for effective management strategies. In contrast, the Middle East and Africa face distinctive challenges, including limited access to healthcare services and a lack of specialized medical facilities in some areas. However, growing awareness and increasing healthcare expenditures are gradually improving the ARDS treatment landscape in these regions. The Asia-Pacific region is witnessing rapid market growth for ARDS treatments and diagnostics, fueled by rising healthcare spending and population growth. China, Japan, and India are conducting this growth due to their large populations and increasing prevalence of respiratory diseases. The region is also seeing a significant uptick in research initiatives and adoption of cutting-edge treatments. Government initiatives to improve healthcare systems are further propelling the market forward in the APAC region.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Respiratory Distress Syndrome Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Respiratory Distress Syndrome Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Respiratory Distress Syndrome Market, highlighting leading vendors and their innovative profiles. These include APEPTICO GmbH, Armstrong Medical Ltd., Athersys, Inc., Bayer AG, Besmed Health Business Corp., Dragerwerk AG & Co. KGaA, EUROSETS S.R.L., F. Hoffmann-La Roche Ltd., Fisher & Paykel Healthcare Corporation Limited, GE HealthCare, Getinge AB, Hamilton Medical AG, HEALIOS K.K., LivaNova PLC, Novartis AG, NRx Pharmaceuticals, Pfizer Inc., Sun Pharmaceutical Industries Limited, Terumo Medical Corporation, United Therapeutics Corporation, and WEINMANN Emergency Medical Technology GmbH + Co. KG.

Market Segmentation & Coverage

This research report categorizes the Acute Respiratory Distress Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Diagnostics
    • Treatment
  • Cause
    • Direct Lung Injury
    • Indirect Lung Injury
  • End-user
    • Hospital
    • Speciality Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acute Respiratory Distress Syndrome Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Respiratory Distress Syndrome Market?

3. What are the technology trends and regulatory frameworks in the Acute Respiratory Distress Syndrome Market?

4. What is the market share of the leading vendors in the Acute Respiratory Distress Syndrome Market?

5. Which modes and strategic moves are suitable for entering the Acute Respiratory Distress Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of ARDS, partly due to rising rates of sepsis, trauma, and infections
      • 5.1.1.2. Advancements in mechanical ventilation and supportive therapies
      • 5.1.1.3. Rising focus on research and development of new pharmaceuticals
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment costs and limited accessibility to advanced care
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing development of personalized medicine approaches
      • 5.1.3.2. Increasing government initiatives and healthcare infrastructure investments
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities for the approval of new therapies and devices
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Increasing need for diagnostics due to its potential for precision medicine application
    • 5.2.2. End-user: Expanding preference for hospitals for management of ARDS
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Acute Respiratory Distress Syndrome Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnostics
  • 6.3. Treatment

7. Acute Respiratory Distress Syndrome Market, by Cause

  • 7.1. Introduction
  • 7.2. Direct Lung Injury
  • 7.3. Indirect Lung Injury

8. Acute Respiratory Distress Syndrome Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospital
  • 8.3. Speciality Clinics

9. Americas Acute Respiratory Distress Syndrome Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Respiratory Distress Syndrome Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Respiratory Distress Syndrome Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. BioAegis scores USD 20millon BARDA contract to develop ARDS therapy
    • 12.3.2. Veru Inc., Reaches Agreement With FDA on a New Phase III Clinical Trial for Sabizabulin for Broader Indication Hospitalized Adult Patients with any Type of Viral Acute Respiratory Distress Syndrome ARDS
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET DYNAMICS
  • FIGURE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TREATMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY DIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY INDIRECT LUNG INJURY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY HOSPITAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY SPECIALITY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 34. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. ARGENTINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 40. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 41. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 42. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 43. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 44. BRAZIL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 45. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 46. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 47. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 48. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 49. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 50. CANADA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 51. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 54. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 55. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 56. MEXICO ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 58. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 59. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 60. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 61. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 62. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 74. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 76. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 78. AUSTRALIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 79. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 82. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 83. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 84. CHINA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 85. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 88. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 89. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. INDIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 94. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 95. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 96. INDONESIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 97. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 98. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 99. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 100. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 101. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 102. JAPAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 103. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 106. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 107. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 108. MALAYSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 109. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 110. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 112. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 114. PHILIPPINES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 115. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 118. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 119. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 120. SINGAPORE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 121. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 124. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. SOUTH KOREA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 130. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 131. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 132. TAIWAN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 133. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 134. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 135. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 136. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 137. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 138. THAILAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 139. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 140. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 141. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 142. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 143. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 144. VIETNAM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 153. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 156. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 157. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. DENMARK ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 162. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 163. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 164. EGYPT ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 165. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 166. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 167. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 168. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 169. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 170. FINLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 171. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 172. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 173. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 174. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 175. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 176. FRANCE ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 177. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 180. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 181. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. GERMANY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 186. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 187. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 188. ISRAEL ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 189. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 190. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 191. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 192. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 193. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 194. ITALY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 196. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 198. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 200. NETHERLANDS ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 201. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 204. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 205. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. NIGERIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 208. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 209. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 210. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 211. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. NORWAY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 214. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 215. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 216. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 217. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 218. POLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 219. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 222. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 223. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. QATAR ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 228. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 229. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. RUSSIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 232. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 234. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 236. SAUDI ARABIA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 238. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 240. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 242. SOUTH AFRICA ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 243. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 246. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 247. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. SPAIN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 252. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 253. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 254. SWEDEN ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 256. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 258. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 260. SWITZERLAND ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 261. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 262. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 263. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 264. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 265. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. TURKEY ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY CAUSE, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED KINGDOM ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 279. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. ACUTE RESPIRATORY DISTRESS SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023